Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Common Share

Net Loss per Common Share

9 Months Ended

Sep. 30, 2022

11. Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period.

The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the nine months ended September 30, 2022:



	Nine Months Ended September 30,
	2022	2021
Warrants to purchase Common Stock	4,030,487	4,535,804
Options to purchase Common Stock	811,924	836,732
Unvested Restricted Stock	18,446,254	16,372,752
Unvested Restricted Stock Units	51,111	209,595
Total	23,339,777	21,954,883